LQDA
NEUTRAL
$38.85
Live
Liquidia Corporation · NASDAQ
Target $50.67
(+30.4%)
$11.85
52W Range
$46.67
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$3.42B
P/E
N/A
ROE
-111.1%
Profit margin
-43.5%
Debt/Equity
4.42
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
Liquidia Corporation presents a high-risk, high-reward profile characterized by a critical Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company has achieved explosive revenue growth (3054.60% YoY) and maintains a strong gross margin of 91.64%, its balance sheet is distressed with a Debt/Equity ratio of 4.42 and an ROE of -111.05%. The market is pricing in significant future success, as evidenced by a Price/Book ratio of 75.73, though insider selling and a bearish technical trend suggest a potential near-term peak. The disconnect between analyst optimism (Buy rating) and deterministic health scores necessitates a neutral stance.
Key Strengths
Explosive revenue growth of 3054.60% YoY
Exceptional gross margins (91.64%) typical of high-value specialty drugs
Positive operating margin (21.50%) suggesting core business viability
Strong analyst support with a target price of $50.67
Healthy short-term liquidity with a current ratio of 2.01
Key Risks
Critical fundamental health (Piotroski F-Score 1/9)
Extreme valuation premiums (Price/Book 75.73, Price/Sales 21.62)
High leverage with a Debt/Equity ratio of 4.42
Consistent history of missing earnings estimates over the last 4 quarters
Strong insider selling pressure (13 sell transactions, 0 buys)
AI Fair Value Estimate
Based on comprehensive analysis
$42.5
+9.4% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
34
Weak
15
85
60
10
0
AI Verdict
Speculative Growth
Key drivers: Hyper-growth in revenue, Severe balance sheet deterioration, Extreme valuation multiples
Confidence
80%
Value
15/100
Graham Number is N/A due to negative earnings; stock trades at a massive premium to book value.
Positives
- Low Forward P/E of 7.42
Watchpoints
- Price/Book of 75.73 is unsustainable
- Price/Sales of 21.62 is extremely high
Future
85/100
Growth rates are outlier-level, driving the bullish analyst sentiment.
Positives
- 3000%+ revenue growth
- Positive operating margin trend
- Strong analyst price targets
Watchpoints
- Dependence on single-product success
Past
60/100
Price action has decoupled from fundamental earnings performance.
Positives
- Massive 5Y price appreciation (+1382.8%)
- Recent 1Y return of +180.9%
Watchpoints
- Poor earnings surprise track record
Health
10/100
Deterministic health scores indicate a company in financial distress despite revenue growth.
Positives
- Current ratio > 2.0
Watchpoints
- Piotroski F-Score 1/9
- Debt/Equity 4.42
- ROE -111.05%
Dividend
0/100
Non-dividend paying growth stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- Negative earnings preclude dividend initiation
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$38.85
Analyst Target
$50.67
Upside/Downside
+30.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LQDA and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LQDA
Liquidia Corporation
Primary
|
+1382.8% | +474.7% | +180.9% | +63.4% | +6.0% | +3.2% |
|
LIVN
LivaNova PLC
Peer
|
-22.5% | +45.9% | +83.9% | +23.9% | +0.8% | -1.6% |
|
BLLN
BillionToOne, Inc.
Peer
|
-32.0% | -32.0% | -32.0% | -32.0% | +2.8% | +6.2% |
|
LEGN
Legend Biotech Corporation
Peer
|
-34.7% | -64.1% | -41.9% | -42.7% | -10.4% | -5.1% |
|
ACAD
ACADIA Pharmaceuticals Inc.
Peer
|
-31.3% | +1.1% | +22.8% | -12.7% | -8.3% | -7.0% |
LQD
Liquidia Corporation
Primary
5Y
+1382.8%
3Y
+474.7%
1Y
+180.9%
6M
+63.4%
1M
+6.0%
1W
+3.2%
LIV
LivaNova PLC
Peer
5Y
-22.5%
3Y
+45.9%
1Y
+83.9%
6M
+23.9%
1M
+0.8%
1W
-1.6%
BLL
BillionToOne, Inc.
Peer
5Y
-32.0%
3Y
-32.0%
1Y
-32.0%
6M
-32.0%
1M
+2.8%
1W
+6.2%
LEG
Legend Biotech Corporation
Peer
5Y
-34.7%
3Y
-64.1%
1Y
-41.9%
6M
-42.7%
1M
-10.4%
1W
-5.1%
ACA
ACADIA Pharmaceuticals Inc.
Peer
5Y
-31.3%
3Y
+1.1%
1Y
+22.8%
6M
-12.7%
1M
-8.3%
1W
-7.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
7.42
PEG Ratio
N/A
P/B Ratio
75.73
P/S Ratio
21.62
EV/Revenue
21.64
EV/EBITDA
-68.03
Market Cap
$3.42B
Profitability
Profit margins and return metrics
Profit Margin
-43.54%
Operating Margin
21.5%
Gross Margin
91.64%
ROE
-111.05%
ROA
-11.5%
Growth
Revenue and earnings growth rates
Revenue Growth
+3054.6%
Earnings Growth
N/A
Q/Q Revenue Growth
+3054.65%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
4.42
High debt
Current Ratio
2.01
Strong
Quick Ratio
1.8
Excellent
Cash/Share
$2.16
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
92.3%
Op. Margin
21.5%
Net Margin
15.8%
Total Assets
$0.3B
Liabilities
$0.3B
Equity
$0.0B
Debt/Equity
6.33x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
91%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-05
$0.15
-55.1% surprise
2025-11-03
$-0.04
+88.7% surprise
2025-08-12
$-0.49
-24.8% surprise
Healthcare Sector Comparison
Comparing LQDA against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-111.05%
This Stock
vs
-86.0%
Sector Avg
+29.1%
(Excellent)
Profit Margin
-43.54%
This Stock
vs
-11.76%
Sector Avg
+270.2%
(Superior)
Debt to Equity
4.42
This Stock
vs
3.51
Sector Avg
+26.2%
(Higher)
Revenue Growth
3054.6%
This Stock
vs
90.15%
Sector Avg
+3288.3%
(Fast Growth)
Current Ratio
2.01
This Stock
vs
3.67
Sector Avg
-45.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LQDA
Liquidia Corporation
|
NEUTRAL | $3.42B | - | -111.1% | -43.5% | $38.85 | |
|
LIVN
LivaNova PLC
|
NEUTRAL | $3.43B | - | -19.2% | -17.5% | $62.78 | Compare |
|
BLLN
BillionToOne, Inc.
|
BEARISH | $3.41B | 569.85 | 2.3% | 1.0% | $74.08 | Compare |
|
LEGN
Legend Biotech Corporation
|
BEARISH | $3.36B | - | -29.1% | -28.8% | $18.16 | Compare |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
NEUTRAL | $3.51B | 8.96 | 39.9% | 36.5% | $20.61 | Compare |
LQDA
Liquidia Corporation
NEUTRAL
Mkt Cap
$3.4B
P/E
-
ROE
-111.1%
Price
$38.85
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-27 | BLOCH STEPHEN M | Director | Sale | 70,234 | $2,533,766 |
| 2026-03-23 | MOOMAW SCOTT | Officer | Sale | 18,314 | $673,752 |
| 2026-03-23 | MOOMAW SCOTT | Officer | Option Exercise | 17,000 | $57,800 |
| 2026-03-13 | SINGH RAMAN | Director | Sale | 20,000 | $720,828 |
| 2026-03-13 | SINGH RAMAN | Director | Option Exercise | 20,000 | $97,200 |
| 2026-03-13 | SAGGAR RAJEEV | Officer | Sale | 35,365 | $1,283,834 |
| 2026-03-13 | KREPP SARAH | Officer | Sale | 16,261 | $617,918 |
| 2026-03-09 | MOOMAW SCOTT | Officer | Sale | 80,000 | $2,825,824 |
| 2026-03-09 | MOOMAW SCOTT | Officer | Option Exercise | 80,000 | $256,821 |
| 2026-03-02 | KASETA MICHAEL | Chief Operating Officer | Sale | 1,165 | $35,626 |
| 2026-03-02 | ADAIR JASON | Officer | Sale | 689 | $21,070 |
| 2026-03-02 | MOOMAW SCOTT | Officer | Sale | 827 | $25,290 |
| 2026-03-02 | SCHUNDLER RUSSELL | General Counsel | Sale | 1,073 | $32,812 |
| 2026-03-02 | KREPP SARAH | Officer | Sale | 276 | $8,440 |
| 2026-03-02 | BOYLE DANA | Officer | Sale | 445 | $13,608 |
BLOCH STEPHEN M
Director
2026-03-27
70,234 shares
·
$2,533,766
MOOMAW SCOTT
Officer
2026-03-23
18,314 shares
·
$673,752
MOOMAW SCOTT
Officer
2026-03-23
17,000 shares
·
$57,800
SINGH RAMAN
Director
2026-03-13
20,000 shares
·
$720,828
SINGH RAMAN
Director
2026-03-13
20,000 shares
·
$97,200
SAGGAR RAJEEV
Officer
2026-03-13
35,365 shares
·
$1,283,834
KREPP SARAH
Officer
2026-03-13
16,261 shares
·
$617,918
MOOMAW SCOTT
Officer
2026-03-09
80,000 shares
·
$2,825,824
MOOMAW SCOTT
Officer
2026-03-09
80,000 shares
·
$256,821
KASETA MICHAEL
Chief Operating Officer
2026-03-02
1,165 shares
·
$35,626
ADAIR JASON
Officer
2026-03-02
689 shares
·
$21,070
MOOMAW SCOTT
Officer
2026-03-02
827 shares
·
$25,290
SCHUNDLER RUSSELL
General Counsel
2026-03-02
1,073 shares
·
$32,812
KREPP SARAH
Officer
2026-03-02
276 shares
·
$8,440
BOYLE DANA
Officer
2026-03-02
445 shares
·
$13,608
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning LQDA from our newsroom.
Newest → oldest
No matching news yet.